Abstract
To reduce the long-term toxicities of immuno - suppressant drugs, corticosteroid-sparing and calcineurin-inhibitor-sparing immunosuppression protocols have become increasingly popular in managing kidney transplant recipients. The most vexing clinical condition caused by antibodies in organ transplants is antibody-mediated rejection. Limitations of the current antibody-mediated rejection therapies include (1) antibody-mediated rejection reversal tends to be gradual rather than prompt, (2) expense, (3) rejection reversal rates below 80%, (4) common appearance of chronic rejection after antibody-mediated rejection treatment, and (5) long-term persistence of donor specific antibodies after therapy. Because these limitations may be due to a lack of effects on mature plasma cells, the effects of bortezomib on mature plasma cells may represent a quantum advance in antihumoral therapy. Our experiences represent the first clinical use of bortezomib as an antihumoral agent in renal allograft recipients in Kuwait. We present 2 cases with resistant-acute antibody-mediated rejection to the standard therapies that were managed successfully with bortezomib.
| Original language | English |
|---|---|
| Pages (from-to) | 406-409 |
| Number of pages | 4 |
| Journal | Experimental and Clinical Transplantation |
| Volume | 10 |
| Issue number | 4 |
| DOIs | |
| State | Published - 2012 |
Keywords
- Antibody-mediated rejection
- Bortezomib
- Renal transplant
Fingerprint
Dive into the research topics of 'Effective therapy for acute antibody-mediated rejection with mild chronic changes: Case report and review of the literature'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver